Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Land & Improvements (2016 - 2023)

China Pharma Holdings' Land & Improvements history spans 13 years, with the latest figure at $389808.0 for Q2 2023.

  • For Q2 2023, Land & Improvements fell 7.12% year-over-year to $389808.0; the TTM value through Jun 2023 reached $389808.0, down 7.12%, while the annual FY2022 figure was $404427.0, 8.46% down from the prior year.
  • Land & Improvements reached $389808.0 in Q2 2023 per CPHI's latest filing, down from $409895.0 in the prior quarter.
  • In the past five years, Land & Improvements ranged from a high of $443697.0 in Q1 2022 to a low of $389808.0 in Q2 2023.
  • Average Land & Improvements over 5 years is $416443.1, with a median of $413603.0 recorded in 2020.
  • Peak YoY movement for Land & Improvements: rose 9.59% in 2021, then fell 8.65% in 2022.
  • A 5-year view of Land & Improvements shows it stood at $403755.0 in 2019, then increased by 6.92% to $431681.0 in 2020, then rose by 2.34% to $441783.0 in 2021, then dropped by 8.46% to $404427.0 in 2022, then dropped by 3.61% to $389808.0 in 2023.
  • Per Business Quant, the three most recent readings for CPHI's Land & Improvements are $389808.0 (Q2 2023), $409895.0 (Q1 2023), and $404427.0 (Q4 2022).